Lung Cancer Clinical Trials
Find clinical trials for lung cancer. Search for lung cancer clinical trials in different cities and states across the United States.
BT8009Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
Sponsor:
BicycleTx Limited
Location:
Code:
NCT04561362
Conditions
Urinary Bladder Neoplasm
Triple Negative Breast Neoplasms
Hormone Receptor Positive, HER2-negative Neoplasms
Hormone Receptor Positive, HER2-low Neoplasms
Breast Neoplasms
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
BT8009
Pembrolizumab
BupivacainePostoperative Pain Control With Lipossomic Extended Release Bupivacaine
Sponsor:
University of Tennessee
Location:
Code:
NCT03560362
Conditions
Pain, Postoperative
Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Bupivacaine liposome
Bupivacaine / Epinephrine
PF-08046054A Study of SGN-PDL1V in Advanced Solid Tumors
Sponsor:
Seagen Inc.
Location:
Code:
NCT05208762
Conditions
Carcinoma, Non-Small-Cell Lung
Squamous Cell Carcinoma of the Head and Neck
Esophageal Squamous Cell Carcinoma
Ovarian Neoplasms
Melanoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
PF-08046054
pembrolizumab
Lung Cancer ScreeningQuebec Lung Cancer Screening PLUS Trial
Sponsor:
Nicole Ezer, MD, FRCPC, MPH
Location:
Code:
NCT05444062
Conditions
COPD
Coronary Artery Calcification
Eligibility Criteria
Sex: All
Age: 55 - 70+
Healthy Volunteers: Not accepted
Interventions
Educational material and treatment recommendations for patients, general practitioners and pharmacists
JIN-A02A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
Sponsor:
J Ints Bio
Location:
Code:
NCT05394831
Conditions
EGFR Mutant Advanced Non-small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
JIN-A02
HBI-2438A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
Sponsor:
HUYABIO International, LLC.
Location:
Code:
NCT05485974
Conditions
Lung Cancer
Non Small Cell Lung Cancer
Colorectal Cancer
Cancer of Pancreas
Colon Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
HBI-2438
NX-1607A Study of NX-1607 in Adults With Advanced Malignancies
Sponsor:
Nurix Therapeutics, Inc.
Location:
Code:
NCT05107674
Conditions
Ovarian Cancer, Epithelial
Gastric Cancer
GastroEsophageal Junction (GEJ) Cancer
Head and Neck Squamous Cell Carcinoma
Metastatic or Unresectable Melanoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
NX-1607
Paclitaxel
IMM-1-104A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Sponsor:
Immuneering Corporation
Location:
Code:
NCT05585320
Conditions
Advanced Solid Tumor
Pancreatic Adenocarcinoma
Malignant Melanoma (Cutaneous)
Non-small Cell Lung Cancer (NSCLC)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
IMM-1-104 Monotherapy (Treatment Group A)
IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)
IMM-1-104 + modified FOLFIRINOX (Treatment Group C)
IMM-1-104 + dabrafenib (Treatment Group D)
IMM-1-104 + pembrolizumab (Treatment Group E)
Local Ablative TherapyA Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)
Sponsor:
Memorial Sloan Kettering Cancer Center
Location:
Code:
NCT05429320
Conditions
Non-small Cell Lung Cancer
Metastatic Non Small Cell Lung Cancer
Nsclc
NSCLC Stage IV
Minimal Residual Disease
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Local ablative therapy
Blood collection to assess for ctDNA